Boehringer Ingelheim
Today, Boehringer Ingelheim, a private Company announced that the FIBRONEER™-ILD trial met its primary endpoint, which was the absolute change from baseline in FVC (mL) at week 52 versus placebo.

FVC is a measure of lung function. 

Initial data readouts of the FIBRONEER™-trials support a generally consistent safety and tolerability profile when compared to the Phase II IPF study, with overall adverse events comparable to those seen in the placebo group.
The Product
Nerandomilast is an investigational oral, preferential inhibitor of the phosphodiesterase 4B (PDE4B). The product has not been approved for use as its safety . . .